Apr. 26 at 7:03 PM
$RLAY
The CEO of Relay is Sanjiv Patel, M.D., who has led the company since March 2017. As of April 20, 2026, his tenure of over 9 years has provided significant stability through the company's clinical-stage expansion and transition to a multi-billion dollar market cap.
Patel's background is rooted in elite pharmaceutical strategy and medical expertise. Before joining Relay, he was Senior Vice President of Emerging Markets at Allergan, where he managed portfolios across 100+ countries.
His tenure at Allergan is particularly relevant; he was a key figure during the company’s high-velocity M&A period, including the Actavis-Allergan merger. This experience is a primary reason institutional whales view him as an "Exit-Ready" CEO.
Patel directly owns 0.8% of Relay's shares, a position worth approximately
$23.14 million as of late April 2026. His total yearly compensation is approximately
$13.08 million, with over 94% of that tied to performance-based bonuses, stock, and options.
